These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway. Yang Q; Xie B; Tang H; Meng W; Jia C; Zhang X; Zhang Y; Zhang J; Li H; Fu B J Exp Clin Cancer Res; 2019 Jun; 38(1):263. PubMed ID: 31208444 [TBL] [Abstract][Full Text] [Related]
63. Inhibition of sphingosine kinase 2 down-regulates ERK/c-Myc pathway and reduces cell proliferation in human epithelial ovarian cancer. Dai L; Wang W; Liu Y; Song K; Di W Ann Transl Med; 2021 Apr; 9(8):645. PubMed ID: 33987343 [TBL] [Abstract][Full Text] [Related]
64. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells. Tsai JJ; Pan PJ; Hsu FT Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898 [TBL] [Abstract][Full Text] [Related]
65. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508 [TBL] [Abstract][Full Text] [Related]
66. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. Qiu Y; Dai Y; Zhang C; Yang Y; Jin M; Shan W; Shen J; Lu M; Tang Z; Ju L; Wang Y; Jiao R; Xia Y; Huang G; Yang L; Li Y; Zhang J; Wong VKW; Jiang Z J Exp Clin Cancer Res; 2018 Dec; 37(1):321. PubMed ID: 30572915 [TBL] [Abstract][Full Text] [Related]
67. Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma. Cai H; Xie X; Ji L; Ruan X; Zheng Z Oncol Lett; 2017 Apr; 13(4):2316-2322. PubMed ID: 28454397 [TBL] [Abstract][Full Text] [Related]
68. Determination of sphingosine kinase 2 activity using fluorescent sphingosine by capillary electrophoresis. Yangyuoru PM; Otieno AC; Mwongela SM Electrophoresis; 2011 Jun; 32(13):1742-9. PubMed ID: 21706498 [TBL] [Abstract][Full Text] [Related]
69. Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Kissel M; Berndt S; Fiebig L; Kling S; Ji Q; Gu Q; Lang T; Hafner FT; Teufel M; Zopf D Oncotarget; 2017 Dec; 8(63):107096-107108. PubMed ID: 29291014 [TBL] [Abstract][Full Text] [Related]
70. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608 [TBL] [Abstract][Full Text] [Related]
71. Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice. Lee SY; Hong IK; Kim BR; Shim SM; Sung Lee J; Lee HY; Soo Choi C; Kim BK; Park TS Hepatology; 2015 Jul; 62(1):135-46. PubMed ID: 25808625 [TBL] [Abstract][Full Text] [Related]
72. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487 [TBL] [Abstract][Full Text] [Related]
73. Contextual fear conditioning is enhanced in mice lacking functional sphingosine kinase 2. Lei M; Shafique A; Shang K; Couttas TA; Zhao H; Don AS; Karl T Behav Brain Res; 2017 Aug; 333():9-16. PubMed ID: 28625547 [TBL] [Abstract][Full Text] [Related]
74. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472 [TBL] [Abstract][Full Text] [Related]
75. Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. Liu XT; Chung LH; Liu D; Chen J; Huang Y; Teo JD; Han XD; Zhao Y; Guan FHX; Tran C; Lee JY; Couttas TA; Liu K; McCaughan GW; Gorrell MD; Don AS; Zhang S; Qi Y Oncogenesis; 2022 Nov; 11(1):67. PubMed ID: 36333295 [TBL] [Abstract][Full Text] [Related]
76. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC. Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740 [TBL] [Abstract][Full Text] [Related]
77. Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-β autocrine loop. Zeng Y; Yao X; Chen L; Yan Z; Liu J; Zhang Y; Feng T; Wu J; Liu X Oncotarget; 2016 Sep; 7(39):63324-63337. PubMed ID: 27556509 [TBL] [Abstract][Full Text] [Related]
78. Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report. Wan Y; Zhu H Front Oncol; 2023; 13():1256137. PubMed ID: 37881484 [TBL] [Abstract][Full Text] [Related]
79. Experience with regorafenib in the treatment of hepatocellular carcinoma. Granito A; Forgione A; Marinelli S; Renzulli M; Ielasi L; Sansone V; Benevento F; Piscaglia F; Tovoli F Therap Adv Gastroenterol; 2021; 14():17562848211016959. PubMed ID: 34104211 [TBL] [Abstract][Full Text] [Related]
80. Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. Feng YQ; Li BA; Feng F; Chen YS; Ren YX; Zhang H; Cao S Onco Targets Ther; 2020; 13():7165-7176. PubMed ID: 32801748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]